Biology of Juvenile Myoclonic Epilepsy
Recruiting now NCT03400371
Run by King's College London · for 10 to 40 · All sexes
What this study is about
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.
Who can join (things the study team will check)
✅ You may be able to join if…
- Diagnosis of Juvenile Myoclonic Epilepsy in accordance with Consensus criteria
- Age of myoclonus onset 10-25 years
- Seizures comprising predominant or exclusive early morning myoclonus of upper extremities
- EEG interictal generalized spikes and/or polyspike and waves with normal background
- Current age 10-40 years
🚫 You may not be able to join if…
- Myoclonus only associated with carbamazepine or lamotrigine therapy
- EEG showing predominant focal interictal epileptiform discharges or abnormal background
- Any evidence of progressive or symptomatic myoclonus epilepsy or focal seizures
- Global learning disability
- Dysmorphic syndrome
- Unable to provide informed consent Regrettably, we are currently unable to accept self-referrals to the BIOJUME study.
Where this trial is running
- Mount Sinai-Beth Israel Medical Center, New York, New York, United States
- St Luke's Roosevelt Hospital, New York, New York, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Hospital for Sick Kids, Toronto, Ontario, Canada
- Charles University, Prague, Czechia
- Danish National Epilepsy Centre, Dianalund, Denmark
- Tallinn Children's Hospital, Tallinn, Estonia
- University Robert Debré, Paris, France
- Commissione Genetica Lega Italiana contro l'Epilepssia, Roma, Italy
- Vestre Viken Health Trust, Oslo, Drammen, Norway
- Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom
- Royal London Hospital, London, United Kingdom
+ 3 more sites.
Who to contact
Deb K Pal, MD PhD · +442078480608 · deb.pal@kcl.ac.uk
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT03400371.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.